Home › USFDA Tracker › Marksans Pharma
Marksans Pharma — USFDA Status
Inspections, Form 483 observations, OAI classifications, warning letters, import alerts and approvals for Marksans Pharma (NSE: MARKSANS, BSE: 524404), from US FDA records and exchange filings.
73
Compliance score (5 years) · how
2
USFDA-inspected plants on record
0
OAI classifications (5y)
1
Form 483s on record (5y)
0
Open warning letters
Latest USFDA record: USFDA inspection classified NAI — 07 Nov 2025 (Verna plant). Source: FDA Data Dashboard.
USFDA events by year
2023
2024
2025
NAIVAIForm 483OAIWarning letterImport alertUS approval
Plants
Full USFDA timeline
07 Nov 2025
NAI — clean
USFDA inspection classified NAI
Verna · FEI 3023677905 · Marksans Pharma Limited, Verna — Drug Quality Assurance (Drugs)
Source: FDA Data Dashboard ↗
17 Apr 2024
VAI — minor issues
USFDA inspection classified VAI
Verna · FEI 3006230648 · Marksans Pharma Limited, Verna — Drug Quality Assurance (Drugs)
Source: FDA Data Dashboard ↗
04 Aug 2023
Form 483
Form 483: 1 observation
Verna · FEI 3006230648 · Failure to submit ADE report
Source: FDA Data Dashboard (citations) ↗
04 Aug 2023
VAI — minor issues
USFDA inspection classified VAI
Verna · FEI 3006230648 · Marksans Pharma Limited, Verna — Bioresearch Monitoring (Drugs)
Source: FDA Data Dashboard ↗
📎 Cite this data: Source: PharmaRoz analysis of FDA inspection data and exchange filings, updated 12 Nov 2026 — https://pharmaroz.com/company/marksans